BP
BIIB icon

Broadleaf Partners’s Biogen BIIB Stock Holding History

Broadleaf Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,812
Closed -$8.59M – 74
2021
Q2 		$8.59M Sell
24,812
-706
-3% -$214K 2.99% 8
2021
Q1 		$7.14M Buy
25,518
+947
+4% +$255K 2.69% 10
2020
Q4 		$6.02M Buy
24,571
+40
+0.2% +$10.3K 2.37% 14
2020
Q3 		$6.96M Buy
24,531
+3,688
+18% +$1.03M 3.07% 8
2020
Q2 		$5.58M Buy
20,843
+193
+0.9% +$58K 2.73% 12
2020
Q1 		$6.53M Sell
20,650
-158
-0.8% -$47.9K 4.21% 6
2019
Q4 		$6.17M Buy
20,808
+4,085
+24% +$1.13M 3.38% 10
2019
Q3 		$3.89M Buy
+16,723
New +$3.89M 2.43% 18
2019
Q1 		– Sell
-9,763
Closed -$2.94M – 53
2018
Q4 		$2.94M Sell
9,763
-169
-2% -$53.9K 2.35% 21
2018
Q3 		$3.51M Buy
9,932
+1,899
+24% +$654K 2.35% 16
2018
Q2 		$2.33M Sell
8,033
-5,833
-42% -$1.64M 1.71% 28
2018
Q1 		$3.8M Buy
13,866
+5,902
+74% +$1.83M 2.92% 12
2017
Q4 		$2.54M Buy
+7,964
New +$2.55M 2.11% 22

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Broadleaf Partners's BIIB Position: Q3 2021 in Review

Broadleaf Partners sold out of Biogen (BIIB) in Q3 2021, closing a stake of 24,812 shares — an estimated $8.59M sold.

Broadleaf Partners first reported a position in BIIB in Q4 2017 and held it in 13 quarters. The position peaked at $8.59M in Q2 2021. 1,040 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

  • Broadleaf Partners reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
  • Broadleaf Partners sold 24,812 Biogen shares in Q3 2021, an estimated $8.59M.
  • Broadleaf Partners first reported a position in Biogen in Q4 2017 and held it in 13 quarters.
  • Broadleaf Partners's Biogen position peaked at $8.59M in Q2 2021.
  • 1,040 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Broadleaf Partners's 13F filing for Q3 2021, filed 9 Nov 2021.